3 August 2018 - - Jersey-based oncology company Novocure's (NASDAQ: NVCR) board of directors has elected Jeryl Hilleman to Novocure's board in July 2018, the company said.

Hilleman is chief financial officer of Intersect ENT (NASDAQ: XENT), a medical device company with commercial products for the treatment of chronic sinusitis.

Prior to joining Intersect ENT, she was chief financial officer of Amyris Inc., a multi-national, renewable products company based in California and Brazil, from January 2008 to June 2012.

Hilleman was a member of the board of directors and chair of the audit committee at Xenoport Inc., a commercial biopharmaceutical company, from January 2004 to July 2018.

She also served as chief financial officer of Symyx Technologies, a research services, software and instrumentation company, Ocera, a biopharmaceutical company, and Cytel, an immunotherapy company.

She is also a director of Minerva Neurosciences (NASDAQ: NERV). Jeri holds an A.B. from Brown University and an MBA from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.

Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

The company's commercialised product is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey,

Novocure has US operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel.